
ACTT-2 findings support FDA emergency use authorization for baricitinib + remdesivir to treat COVID-19
November 20, 2020
The U.S. FDA granted emergency use authorization (EUA) for the use of baricitinib in combination with remdesivir to treat COVID-19 in hospitalized adults and children at least two years of age requiring supplemental oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation.